{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:45:49Z","timestamp":1783741549919,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00970","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T04:39:53Z","timestamp":1569904793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients"],"prefix":"10.3389","volume":"9","author":[{"given":"Mutlay","family":"Sayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Abou Yehia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Toppmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Ohri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Haffty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/stem.160413","article-title":"The HER-2\/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy","volume":"3","author":"Ross","year":"1998","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","article-title":"Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"B13","first-page":"1113","article-title":"Sensitization of breast cancer cells to radiation by trastuzumab","volume":"2","author":"Liang","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"B14","first-page":"1347","article-title":"Monoclonal antibody to HER-2\/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene","volume":"59","author":"Pietras","year":"1999","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10549-018-5053-y","article-title":"Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy","volume":"174","author":"Abouegylah","year":"2018","journal-title":"Breast Cancer Res Treat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2478\/raon-2018-0011","article-title":"Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer","volume":"52","author":"Marinko","year":"2018","journal-title":"Radiol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.21873\/invivo.11322","article-title":"Cardiotoxicity assessment after different adjuvant hypofractionated radiotherapy concurrently associated with trastuzumab in early breast cancer","volume":"32","author":"Bonzano","year":"2018","journal-title":"In Vivo"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","article-title":"Cardiovascular disease mortality among breast cancer survivors","volume":"27","author":"Bradshaw","year":"2016","journal-title":"Epidemiology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.cjca.2016.04.008","article-title":"Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients","volume":"32","author":"Johnson","year":"2016","journal-title":"Can J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMc1304601","article-title":"Ischemic heart disease after breast cancer radiotherapy","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2013.51.1261","article-title":"Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study","volume":"32","author":"Vaz-Luis","year":"2014","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1200\/JCO.1994.12.3.447","article-title":"Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy","volume":"12","author":"Cuzick","year":"1994","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","article-title":"Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries","volume":"6","author":"Darby","year":"2005","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/djk064","article-title":"Long-term risk of cardiovascular disease in 10-year survivors of breast cancer","volume":"99","author":"Hooning","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijrobp.2005.01.029","article-title":"The incidence and functional consequences of RT-associated cardiac perfusion defects","volume":"63","author":"Marks","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/JCO.2016.70.7158","article-title":"Hypofractionated postmastectomy radiation therapy is safe and effective: first results from a prospective phase II trial","volume":"35","author":"Khan","year":"2017","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jamaoncol.2015.2590","article-title":"Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort","volume":"1","author":"Jagsi","year":"2015","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s12032-014-0891-x","article-title":"Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series","volume":"31","author":"Meattini","year":"2014","journal-title":"Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jama.2015.1644","article-title":"Hypofractionated whole breast irradiation for early-stage breast cancer\u2013reply","volume":"313","author":"Bekelman","year":"2015","journal-title":"JAMA"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T04:39:56Z","timestamp":1569904796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":33,"alternative-id":["10.3389\/fonc.2019.00970"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00970","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"article-number":"970"}}